Spinal Muscular Atrophy (SMA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Spinal Muscular Atrophy (SMA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in SMA therapeutics.

• More than 138,844 diagnosed prevalent cases of 5q SMA (types I–IV) are anticipated in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for SMA.
• Only a handful of approved therapeutic drugs are currently available for the treatment of SMA, all belonging to a single key mechanism of survival motor neuron (SMN) protein upregulation.
• The late-stage pipeline for SMA includes one drug in pre-registration and five drugs in Phase III.
• The clinical trial space in SMA consists of almost an equal mix of commercial as well as academic sponsors, with Japan emerging as the key country for conducting Phase III trials.
• Licensing agreements were the most prominent deals type ventured in the SMA space globally.

Scope

GlobalData’s SMA: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the SMA market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global SMA market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.